Eleven states require schools to stock epinephrine, according to Food Allergy Research & Education, an allergy advocacy group that counts Mylan as one of its corporate sponsors. A provision in the Federal Aviation Administration …
Mylan N.V. (NASDAQ: MYL) just has been unable to recover from its EpiPen pricing hike issue. Shares were down over 4% on Thursday morning, and now the stock is dangerously close to a 52-week low. It is at the lowest stock price …
This quick video takes a look at Mylan (MYL) ahead of its earnings report. The pharma company has been under pressure for much of 2016 while a bottom 33% industry rank isn’t helping matters either. Even more troubling than the weak …
Mylan isn’t the only company riding the EpiPen roller coaster of late. The pharmaceutical company announced Monday that it plans to sell a generic version of EpiPen, its best-selling product. This news came after a national uproar over the …
Fortune points out he even had some choice words on the Mylan matter just a few days ago, though his true motives remain unclear. Mylan's stock spiked up nearly 1 percent on Monday, although it is down 24 percent on the year.
Lawmakers seethed, parents broke into tears at pharmacy counters, regulators opened investigations, competitors raced to come up with cheaper alternatives, and Mylan’s stock tumbled 29 percent. Further Reading Rage mounts against …
But instead she can now add some shadily-timed trading of Mylan stock to her growing list of “Things That Suck For Me Right Now.” Heather Bresch, the CEO at the center of EpiPen’s 471% price hike, sold 100,200 of her shares earlier this …
This week is almost all about the presidential election, which will resound throughout the stock market -- especially if Donald Trump is elected. Far more studies than not say the markets will tank if Trump surprises most pundits and …
Mylan's stock price surged after their price increase strategy, going from as low as $14.84 per share in 2007, when it first bought EpiPens, to as high as $49.09 on Monday. Attention given to the rising price of the pens has prompted calls …
There's no justification for these price hike", the drug pricing issue will remain in focus (Read more: Did Hillary Clinton's Tweet Cause the Sell-Off in Mylan Stock?). Novartis Scores Another Win in Biosimilar Segment: Novartis scored …